microarray mrna data (WholeGenome LLC)
90
Structured Review
WholeGenome LLC
microarray mrna data
Microarray Mrna Data, supplied by WholeGenome LLC, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/microarray+mrna+expression+data/microarray+mrna+data/pm22515606-22-0-0
Average 90 stars, based on 1 article reviews
Microarray Mrna Data, supplied by WholeGenome LLC, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/microarray+mrna+expression+data/microarray+mrna+data/pm22515606-22-0-0
Average 90 stars, based on 1 article reviews
microarray mrna data - by Bioz Stars,
2026-09
90/100 stars
Images
Related Articles
Microarray:Article Title: Highlights from the latest articles in breast cancer pharmacogenomics. Article Snippet: ISSN 1462-2416 10.2217/PGS.12.20 © 2012 Future Medicine Ltd Pharmacogenomics (2012) 13(6), 645–649 645 Chemoresistance to many cancer thera peutic drugs is common and results in cancer mortality due to disease progres sion. miRNAs are short ncRNAs which act as negative gene regulators and have been recognized to target key genes implicated in the mechanisms of chemoresistance [1].. Overexpression of the polycomb histone methyltransferase, EZH2, contributes to pancreatic, prostate and breast cancer progression [2].. High EZH2 levels are also associated with poor response to tamoxifen therapy in metastatic breast cancer patients [3] and resistance to gemcitabine and doxo rubicin in pancreatic cancer cells [2]. Expressing:Article Title: Highlights from the latest articles in breast cancer pharmacogenomics. Article Snippet: ISSN 1462-2416 10.2217/PGS.12.20 © 2012 Future Medicine Ltd Pharmacogenomics (2012) 13(6), 645–649 645 Chemoresistance to many cancer thera peutic drugs is common and results in cancer mortality due to disease progres sion. miRNAs are short ncRNAs which act as negative gene regulators and have been recognized to target key genes implicated in the mechanisms of chemoresistance [1].. Overexpression of the polycomb histone methyltransferase, EZH2, contributes to pancreatic, prostate and breast cancer progression [2].. High EZH2 levels are also associated with poor response to tamoxifen therapy in metastatic breast cancer patients [3] and resistance to gemcitabine and doxo rubicin in pancreatic cancer cells [2]. |
